• Explore /
  • Poster
  • / Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).

Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Ruihua Xu

Sun Yat-Sen University Cancer Center, Guangzhou, China

Ruihua Xu , Jin Li , Yu-Xian Bai , Yanhong Deng , Lei Yang , Haijun Zhong , Zhendong Chen , Hongming Pan , Weijian Guo , Yongqian Shu , Ying Yuan , Jianming Xu , Lin Shen , Ning Wang , Xin Wang , Haidong Chi , Jack Peng , Ye Hua , Weiguo Su , Shukui Qin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02314819

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3537)

DOI

10.1200/JCO.2018.36.15_suppl.3537

Abstract #

3537

Poster Bd #

30

Abstract Disclosures

Similar Posters

First Author: Yu-Xian Bai

First Author: Arvind Dasari

First Author: Sebastian Stintzing

Poster

2016 Gastrointestinal Cancers Symposium

Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.

Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.

First Author: Sanjay Goel